G4-QuadScreen: A Computational Tool for Identifying Multi-Target-Directed Anticancer Leads against G-Quadruplex DNA.

FID assays FRET experiments G4 quadruplex MTT assays cancer drug design molecular docking multi-tasking QSAR virtual screening

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
27 Jul 2023
Historique:
received: 01 06 2023
revised: 16 07 2023
accepted: 21 07 2023
medline: 12 8 2023
pubmed: 12 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

The study presents 'G4-QuadScreen', a user-friendly computational tool for identifying MTDLs against G4s. Also, it offers a few hit MTDLs based on in silico and in vitro approaches. Multi-tasking QSAR models were developed using linear discriminant analysis and random forest machine learning techniques for predicting the responses of interest (G4 interaction, G4 stabilization, G4 selectivity, and cytotoxicity) considering the variations in the experimental conditions (e.g., G4 sequences, endpoints, cell lines, buffers, and assays). A virtual screening with G4-QuadScreen and molecular docking using YASARA (AutoDock-Vina) was performed. G4 activities were confirmed via FRET melting, FID, and cell viability assays. Validation metrics demonstrated the high discriminatory power and robustness of the models (the accuracy of all models is ~>90% for the training sets and ~>80% for the external sets). The experimental evaluations showed that ten screened MTDLs have the capacity to selectively stabilize multiple G4s. Three screened MTDLs induced a strong inhibitory effect on various human cancer cell lines. This pioneering computational study serves a tool to accelerate the search for new leads against G4s, reducing false positive outcomes in the early stages of drug discovery. The G4-QuadScreen tool is accessible on the ChemoPredictionSuite website.

Identifiants

pubmed: 37568632
pii: cancers15153817
doi: 10.3390/cancers15153817
pmc: PMC10416877
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Nucleic Acids Res. 2013 Jan;41(Database issue):D1115-23
pubmed: 23161677
J Chem Inf Model. 2019 Jun 24;59(6):2538-2544
pubmed: 31083984
Anal Bioanal Chem. 2011 Jul;400(10):3419-27
pubmed: 21528379
Angew Chem Int Ed Engl. 2023 Mar 6;62(11):e202211358
pubmed: 36584293
Br J Cancer. 2019 Mar;120(6):612-620
pubmed: 30792533
Oncogene. 2007 Nov 29;26(54):7560-8
pubmed: 17546049
Altern Lab Anim. 2005 Oct;33(5):445-59
pubmed: 16268757
FEBS J. 2010 Mar;277(5):1118-25
pubmed: 19951354
Biochimie. 2018 Sep;152:134-148
pubmed: 29966734
J Chem Inf Model. 2015 Nov 23;55(11):2324-37
pubmed: 26479676
ChemMedChem. 2018 May 8;13(9):869-893
pubmed: 29512884
Pharm Res. 2006 May;23(5):1031-7
pubmed: 16715394
Mol Oncol. 2012 Apr;6(2):155-76
pubmed: 22440008
ACS Chem Biol. 2016 Jun 17;11(6):1720-8
pubmed: 27097021
Nucleic Acids Res. 2022 Jan 7;50(D1):D150-D160
pubmed: 34718746
Chembiochem. 2020 Apr 1;21(7):963-970
pubmed: 31621996
Bioinformatics. 2014 Oct 15;30(20):2981-2
pubmed: 24996895
J Chem Inf Model. 2016 Jul 25;56(7):1243-52
pubmed: 27280890
J Cheminform. 2021 Jan 10;13(1):2
pubmed: 33423696
Clin Ther. 2016 Jul;38(7):1551-66
pubmed: 27158009
Nucleic Acids Res. 2021 Jul 9;49(12):6638-6659
pubmed: 33978760
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Nature. 2004 Nov 18;432(7015):294-7
pubmed: 15549090
Nat Rev Mol Cell Biol. 2020 Aug;21(8):459-474
pubmed: 32313204
Drug Discov Today. 2020 Jul;25(7):1213-1222
pubmed: 32387261
Clin Transl Med. 2018 Jan 17;7(1):3
pubmed: 29340951
Molecules. 2019 Jan 22;24(3):
pubmed: 30678288
ChemMedChem. 2014 May;9(5):899-911
pubmed: 24729465
ACS Omega. 2023 Jun 12;8(25):23148-23167
pubmed: 37396211
BBA Clin. 2015 Apr 18;3:280-8
pubmed: 26673349
Mol Divers. 2015 May;19(2):347-56
pubmed: 25754075
J Comput Chem. 2011 May;32(7):1466-74
pubmed: 21425294
J Chem Inf Model. 2021 Jul 26;61(7):3159-3165
pubmed: 34251213
Org Biomol Chem. 2008 Feb 21;6(4):627-36
pubmed: 18264563
J Biomol Struct Dyn. 2019 Mar;37(5):1282-1306
pubmed: 29578387
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Jyotsna Bhat-Ambure (J)

MolDrug AI Systems SL, c/Olimpia Arozena Torres, 46018 Valencia, Spain.

Pravin Ambure (P)

ProtoQSAR SL, Centro Europeo de Empresas Innovadoras (CEEI), Parque Tecnológico de Valencia, 46980 Valencia, Spain.

Eva Serrano-Candelas (E)

ProtoQSAR SL, Centro Europeo de Empresas Innovadoras (CEEI), Parque Tecnológico de Valencia, 46980 Valencia, Spain.

Cristina Galiana-Roselló (C)

Department of Inorganic Chemistry, Institute of Molecular Science, University of Valencia, 46980 Valencia, Spain.

Ariadna Gil-Martínez (A)

Department of Inorganic Chemistry, Institute of Molecular Science, University of Valencia, 46980 Valencia, Spain.

Mario Guerrero (M)

Biochemistry and Molecular Biology Unit, Biomedicine Department, Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain.

Margarita Martin (M)

Biochemistry and Molecular Biology Unit, Biomedicine Department, Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain.
Clinical and Experimental Respiratory Immunoallergy (IRCE), Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.

Jorge González-García (J)

Department of Inorganic Chemistry, Institute of Molecular Science, University of Valencia, 46980 Valencia, Spain.

Enrique García-España (E)

Department of Inorganic Chemistry, Institute of Molecular Science, University of Valencia, 46980 Valencia, Spain.

Rafael Gozalbes (R)

MolDrug AI Systems SL, c/Olimpia Arozena Torres, 46018 Valencia, Spain.
ProtoQSAR SL, Centro Europeo de Empresas Innovadoras (CEEI), Parque Tecnológico de Valencia, 46980 Valencia, Spain.

Classifications MeSH